HISTORY OF THIS FRENCH COMPANY

1997 Initial Public Offering

A decisive milestone has been reached: the company’s listing on Euronext Paris and a capital raise to fund an ambitious growth strategy.

From that point on, Eurofins adopted a model that would become its strength: organic growth combined with targeted acquisitions of specialized laboratories. 

1988–1996: The Early Years

Eurofins is gradually developing this technology to:

  • detect fraud in wine (addition of sugar);
  • authenticate fruit juices;
  • test natural flavors;
  • verify the geographic origin of many food products.

 

The company quickly earned a reputation for scientific excellence, 
and opened its first laboratories outside of France, notably in the United Kingdom and the United States.

1998–2005 - International Expansion

The group is also expanding its areas of activity:

  • food analysis;
  • environment;
  • pharmaceuticals;
  • biotechnology;
  • genomics.

Eurofins is acquiring numerous laboratories in:

  • Germany;
  • the United Kingdom;
  • the United States;
  • Scandinavia;
  • the Benelux countries.

In 2001, Eurofins developed Eurofins TAG, a system for the genetic traceability of meat, particularly in the context of the BSE crisis (“mad cow disease”). 

2006–2012: A Change in Scale

  • plusieurs dizaines de laboratoires sont acquis ;
  • Eurofins devient un acteur majeur des analyses pharmaceutiques
  • le groupe investit massivement dans les biotechnologies, la biologie moléculaire et les analyses environnementales.

Sa présence devient véritablement mondiale.

2013–2019 Global Leader

Eurofins is pursuing a very aggressive acquisition strategy, and the group:

  • has more than 800 laboratories;
  • employs tens of thousands of people;
  • has developed more than 200,000 analytical methods.

2021–2024 Inclusion in the CAC 40 Index

His main areas of expertise

  • 2021: Eurofins joins the CAC 40 index, a testament to its economic significance among France’s largest publicly traded companies.
  • 2023–2024: After the pandemic ends, the group refocuses its growth on its core businesses.
  • food safety;
  • pharmaceutical industry;
  • clinical trials;
  • environment;
  • cosmetics;
  • veterinary medicine;
  • genomics;
  • medical biology.